Monday 23 July 2012

Aurobindo Pharmaceutical gets USFDA acceptance for diabetic issues drug



USA: Aurobindo Pharmaceutical said it has obtained last acceptance from the US health regulator to produce and industry Metformin Hydrochloride pills used for the diabetic issues.

“The organization has obtained last acceptance from the Combined Declares Food and Medication Management (USFDA) to produce and industry Metformin Hydrochloride prolonged release pills USP,” Aurobindo Pharmaceutical said in a declaration.
The acceptance is for pills in the strong points of 500 mg and 750 mg and the product is prepared for release, it included. Metformin Hydrochloride prolonged release pills USP, 500 mg and 750 mg, are general comparative to Bristol Myers Squibb’s Glucophage XR prolonged release pills in the same strong points.

The pills are indicated to control blood sugar stages in sufferers with type II diabetic issues. Aurobindo Pharmaceutical currently has a complete of 153 shortened new drug program (ANDA) mortgage approvals from USFDA, the organization said.

Shares of Aurobindo Pharmaceutical were dealing at Rs 108.85 each in manufactured business on the BSE up 0.51 % from its past near.

No comments:

Post a Comment